NASDAQ:TLSA Tiziana Life Sciences Q4 2025 Earnings Results & Report $1.19 +0.06 (+5.31%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$1.18 -0.01 (-0.92%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Tiziana Life Sciences reported Q4 2025 earnings on May 1, 2026. The company reported EPS of -$0.2750. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMay 1, 2026TimeAfter Market Closes Tiziana Life Sciences EPS ResultsActual EPS-$0.2750Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ATiziana Life Sciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Tiziana Life Sciences Q4 2025 Earnings FAQ Did Tiziana Life Sciences beat earnings estimates for Q4 2025? Tiziana Life Sciences (NASDAQ:TLSA) reported earnings of -$0.2750 per share for Q4 2025. The report was announced on Friday, May 1, 2026. Tiziana Life Sciences Earnings HeadlinesTiziana Life Sciences (TLSA) Gets a Buy from BTIGOctober 7, 2026 | theglobeandmail.comTiziana Files For Orphan Drug Designation For Foralumab In MSASeptember 30, 2026 | rttnews.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now. | Stansberry Research (Ad)Tiziana Seeks FDA Orphan Drug Designation For Intranasal ForalumabSeptember 30, 2026 | rttnews.comTiziana Life Sciences seeks FDA orphan drug status for nasal MSA therapySeptember 30, 2026 | proactiveinvestors.comTiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)September 30, 2026 | finance.yahoo.comSee More Tiziana Life Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tiziana Life Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tiziana Life Sciences and other key companies, straight to your email. Email Address About Tiziana Life SciencesTiziana Life Sciences (NASDAQ:TLSA). is a clinical-stage biotechnology company focused on developing therapies that regulate the immune system and address inflammatory and neurodegenerative diseases. The company’s research centers on treatments designed to modulate immune responses without broadly suppressing immune function. Tiziana’s lead product candidate is foralumab, a fully human monoclonal antibody that targets the CD3 receptor on T cells. The company is developing an intranasal formulation of foralumab for conditions associated with neuroinflammation, including non-active secondary progressive multiple sclerosis and Alzheimer’s disease. Tiziana has also investigated the candidate in other inflammatory conditions. The company’s development activities involve clinical research and collaborations in the United States and other regions. Tiziana Life Sciences was founded by Dr. Kunwar Shailubhai, who has served as its chief executive officer and chief scientific officer and oversees the company’s scientific and development strategy.View Tiziana Life Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
